Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

Fazlollah Shokri; Saeed Rezapoor; Masoud Najafi; Mohsen Asadi; Mohammad Karimi Alavije; Moussa Abolhassani; Mohammad Hossein Moieneddin; Amir Muhammad Ashrafi; Narges Gholipour; Parisa Naderi; Jamshid Yazdani Charati; Reza Alizadeh-Navaei; Majid Saeedi; Mohsen Heidary; Mostafa Rostamnezhad

doi:10.1016/j.vacun.2022.09.077

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

Vacunas. 2023 Apr-Jun;24(2):141-149. doi: 10.1016/j.vacun.2022.09.077. Epub 2022 Oct 4.

Authors

Fazlollah Shokri¹, Saeed Rezapoor², Masoud Najafi^{3

4}, Mohsen Asadi⁵, Mohammad Karimi Alavije⁶, Moussa Abolhassani⁷, Mohammad Hossein Moieneddin⁸, Amir Muhammad Ashrafi⁸, Narges Gholipour⁹, Parisa Naderi¹⁰, Jamshid Yazdani Charati¹¹, Reza Alizadeh-Navaei¹², Majid Saeedi¹³, Mohsen Heidary¹⁴, Mostafa Rostamnezhad¹⁵

Affiliations

¹ Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Department of Radiology, Imam Khomeini Hospital, Amol, Iran.
³ Medical Technology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
⁴ Radiology and Nuclear Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran.
⁵ Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Department of Infectious Disease, Imam Reza Hospital, Amol, Iran.
⁷ Inv. Member, International Federation of Inventors' Associations-IFIA, Geneva, Switzerland.
⁸ Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran.
⁹ Department of Critical Care Nursing, School of Nursing and Midwifery (Nasibeh), Mazandaran University of Medical Sciences, Sari, Iran.
¹⁰ Department of Biology, Faculty of Cellular and Molecular Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
¹¹ Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
¹² Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
¹³ Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.
¹⁴ Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
¹⁵ Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Abstract
in English, Spanish

Introduction: Coronavirus disease 2019 (COVID-19) is the most critical issue in nowadays medicine. We aimed to evaluate the use and therapeutic outcomes of oseltamivir, an antiviral drug for patients with COVID-19.

Materials and method: In an observational study conducted at Imam Khomeini Hospital in Amol, Iran, data for 544 patients with laboratory and CT scan result confirmed COVID-19 were retrospectively collected between February 24th and April 13th 2020. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression was used to evaluate the effect of oseltamivir on the outcome of treatment. Logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir.

Results: Kaplan-Meier and logrank test showed no significant reduction in hospitalization time and survival rate following treatment with oseltamivir. However, a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected.

Conclusion: Administration of oseltamivir for patients with COVID-19 didn't show any improvement in hospitalization duration and survival rate.

Introducción: la enfermedad por coronavirus 2019 (COVID-19) es el tema más crítico en la medicina actual. Nuestro objetivo fue evaluar el uso y los resultados terapéuticos de oseltamivir, un medicamento antiviral para pacientes con COVID-19.

Materiales y método: en un estudio observacional realizado en el Hospital Imam Khomeini en Amol, Irán, los datos de 544 pacientes con resultados de laboratorio y tomografía computarizada confirmados de COVID-19 se recopilaron retrospectivamente entre el 24 de febrero y el 13 de abril de 2020. Para comparar las características de los pacientes en función del género se utilizó la prueba de chi-cuadrado. Se utilizó regresión logística para evaluar el efecto de oseltamivir en el resultado del tratamiento. Se utilizó la prueba de rango logarítmico para comparar la duración de la estancia hospitalaria en personas tratadas con oseltamivir y otros fármacos distintos del oseltamivir.

Resultados: Kaplan–Meier y la prueba de rango logarítmico no mostraron una reducción significativa en el tiempo de hospitalización y la tasa de supervivencia después del tratamiento con oseltamivir. Sin embargo, se detectó un aumento significativo en el recuento de linfocitos y una reducción del nivel de proteína C reactiva (PCR).

Conclusión: la administración de oseltamivir para pacientes con COVID-19 no mostró ninguna mejora en la duración de la hospitalización y la tasa de supervivencia.

Keywords: COVID-19; Hospitalization; Oseltamivir; SARS-CoV-2.

Abstract in English, Spanish

Abstract
in English, Spanish